BMC Bioinformatics

Table 3 Distribution of targets with respect to the cancer type and genes from which the peptides are derived

From: In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy

	Tumor	Gene	Count
1	BLCA	MAGEA12	16
2	BLCA	MAGEA9B	13
3	BLCA	MAGEA3	12
4	BLCA	MAGEA6	10
5	BLCA	MAGEA4	9
6	BRCA	ANKRD30A	23
7	CESC	SMC1B	22
8	DLBC	NLRP4	47
9	DLBC	MAGEA9B	13
10	DLBC	C7orf72	4
11	ESCA	MAGEA3	12
12	ESCA	MAGEA6	10
13	ESCA	MAGEA4	9
14	GBM	RPE65	15
15	HNSC	MAGEA3	12
16	HNSC	MAGEA6	10
17	HNSC	MAGEA4	9
18	KICH	CNTNAP5	35
19	LAML	UMODL1	54
20	LAML	DNTT	16
21	LGG	RPE65	15
22	LIHC	MAGEA3	12
23	LIHC	MAGEA1	11
24	LIHC	MAGEA6	10
25	LIHC	COX7B2	5
26	LUSC	MAGEA9B	13
27	LUSC	MAGEA11	13
28	LUSC	MAGEA3	12
29	LUSC	MAGEA1	11
30	LUSC	MAGEA6	10
31	LUSC	MAGEA4	9
32	OV	EPYC	8
33	PRAD	TGM4	16
34	PRAD	POTEM	7
35	PRAD	KLKP1	1
36	SKCM	MAGEC2	18
37	SKCM	MAGEA12	16
38	SKCM	MAGEA3	12
39	SKCM	TRIM51	11
40	SKCM	MAGEA6	10
41	SKCM	DSCR8	5
42	STAD	MAGEA3	12
43	STAD	MAGEA6	10
44	UCEC	MTRNR2L1	2
45	UCS	MAGEA9B	13
46	UCS	MAGEA4	9
47	UCS	DSCR8	5

See Additional file 1 for the description of TCGA tumor types

Back to article page

ISSN: 1471-2105

Contact us

General enquiries: journalsubmissions@springernature.com